|
|
Vaccine Comparison
|
BPZE1- FHA (H1N1/PR8 influenza A virus) |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004650
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: Recombinant protein preparation
- Description: One, two and three copies of the Cys-containing ectodomain of matrix protein 2 (M2e) from influenza A virus were genetically fused to full length FHA and expressed in BPZE1 (Li et al., 2011).
- Detailed Gene Information: Click Here.
- Vector: (Mielcarek et al., 2006)
- Preparation: One, two and three copies of the Cys-containing ectodomain of matrix protein 2 (M2e) from influenza A virus were genetically fused to full length FHA and expressed in BPZE1 (Li et al., 2011).
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Li et al., 2011: Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, Alonso S. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine. 2011; 29(33); 5502-5511. [PubMed: 21624415].
Mielcarek et al., 2006: Mielcarek N, Debrie AS, Raze D, Quatannens J, Engle J, Goldman WE, Locht C. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine. 2006; 24 Suppl 2; S2-54-5. [PubMed: 16823926].
|
|
Influenza virus CTA1-3M2e-DD protein vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0002980
- Type: Subunit vaccine
- Status: Research
- Antigen: Influenza A virus (A/Puerto Rico/8/34(H1N1)) matrix protein 2 (M2)
- M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: Recombinant protein preparation
- Description: The fusion proteins were expressed in E. coli DH5 cells, transformed with the expression vectors for the CTA1-DD, CTA1-M2e-DD or the CTA1-3M2e-DD fusion proteins, and grown in 500 ml cultures over night in SYPPG medium with 100 μg/ml carbenicillin, at 37 °C. The cells were harvested by centrifugation and the fusion proteins, produced as inclusion bodies, were washed before extraction by treatment with 8 M urea. After refolding the proteins by slowly diluting them 35–40x in Tris–HCl pH 7.4 at +4 °C, the fusion proteins were purified in two steps, by ion exchange and size exclusion chromatography. After concentration and sterile filtration the purified fusion proteins were stored in PBS at −80 °C until use (Eliasson et al., 2008).
- Detailed Gene Information: Click Here.
- Adjuvant: cholera toxin A1-subunit-ProteinA D-fragment fusion protein
- Immunization Route: Intranasal
|
| References |
Eliasson et al., 2008: Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9); 1243-1252. [PubMed: 18243429].
|
|
Influenza virus DNA vaccine M2-DNA/M2-Ad |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004568
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Vector: VR1012 priming, replication-incompetent adenovirus boost (Tompkins et al., 2007)
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].
|
|
Influenza virus DNA vaccine pDNA encoding M2 and NP |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004355
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: DNA vaccine construction
- Description: This DNA vaccine used the plasmid vector VR10551 to express highly‑conserved influenza gene M2 (Jimenez et al., 2007).
- Detailed Gene Information: Click Here.
- NP from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: DNA vaccine construction
- Description: This DNA vaccine used the plasmid vector VR10551 to express highly‑conserved influenza gene NP (Jimenez et al., 2007).
- Detailed Gene Information: Click Here.
- Vector: VR10551 (Jimenez et al., 2007)
- Immunization Route: intranasal immunization
|
| References |
Jimenez et al., 2007: Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Human vaccines. 2007; 3(5); 157-164. [PubMed: 17637571].
|
|
Influenza virus NS1 mutant vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0002981
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse, pig, horse, macaque
- NS1 from Influenza virus
gene engineering:
- Immunization Route: intranasal immunization
|
| References |
Richt and García-Sastre, 2009: Richt JA, García-Sastre A. Attenuated influenza virus vaccines with modified NS1 proteins. Current topics in microbiology and immunology. 2009; 333; 177-195. [PubMed: 19768406].
|
|
M2 mutant from Influenza A |
| Vaccine Information |
- Product Name: M2KO
- Vaccine Ontology ID: VO_0004287
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
gene engineering:
- Type: Gene mutation
- Description: This M2 gene is from Influenza A (Watanabe et al., 2009).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
| References |
Watanabe et al., 2009: Watanabe S, Watanabe T, Kawaoka Y. Influenza A virus lacking M2 protein as a live attenuated vaccine. Journal of virology. 2009; 83(11); 5947-5950. [PubMed: 19321619].
|
|
